NCT04376866View on ClinicalTrials.gov

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

June 28, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2028

Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
DRUG

Toripalimab

anti-PD-1 antibody

Trial Locations (1)

530021

RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

All Listed Sponsors
lead

Cancer Hospital of Guangxi Medical University

OTHER

NCT04376866 - Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter